FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W98494543> ?p ?o ?g. }

• W98494543 abstract "Abstract Changes in the production of monoclonal intact immunoglobulin (M-Ig) or of serum free light chains (sFLC) during symptomatic MM patients’ relapse eventually reflect molecular myeloma cells changes and / or reveal clonal cell competition. We aimed to study changes in Ig production (CIg) in symptomatic MM patients and to evaluate related frequency and corresponding specific disease characteristics. Patients and Methods 232 symptomatic MM patients with available follow-up sFLC measurements, were retrospectively studied. Light chain escape (LCE) was defined as sFLC increase with stable or falling M-Ig concentrations, M-Ig escape (MCE) as decreasing sFLC with increasing M-Ig, de-differentiation (DD) as clinical relapse with normal or decreased M-Ig and sFLC and Clonal Domination (CD) as normalization of formerly increased IgG, IgA or FLC in relapsing patients presenting increase of another component. Survival was calculated from diagnosis or from CIg date to last follow-up or death, survival curves were plotted by Kaplan-Meyer Method and assessed by the log-rank test. Results There were 94 women and 128 men, median aged 66 years; 29%, 42%, 29% and 22%, 30%, 48% were in Durie-Salmon and ISS stages I, II, III and 1, 2, 3 respectively. MM type was IgG MM in 59%, IgA in 21%, light chain only in 17%, IgD in 2% and non-secretory in1%. Median survival of the whole cohort was 46,4 months. CIg was observed in 39 patients (17%), consisting in LCE in 15 patients (6%), MCE in 7 (3%), DD in 5 (2%) and CD in 10 (4%); two additional patients (1 IgD and 1 LC) transiently produced another monoclonal component that was IgG in both cases, while in stringent complete remission. In CD patients, the dominated clone was IgG in 9 out of 10 patients, while the dominating one was LC in 8 and IgA in 2. LCE and MCE were more frequent in IgG patients. The median number of treatment lines received prior CIg was 5 for LCE, 4 for MCE, 2 for DD and 1 for CD. LCE and MCE patients had all received novel agents and/or ASCT. The median time from CIg to last follow-up or death was 2,6 months (2,2-3) for LCE, 3,3 months (2,2-4,4) for MCE, 6,3 months (1,1-11,6) for DD and 31,1 months (23,6-38,6) for CD. Patients presenting LCE, MCE and DD had a considerably shorter survival after CIg compared to patients presenting CD (p=0,0002). However because CIg was usually a late event in the course of the disease the overall survival of CIg patients was 60,6 months. In conclusion, LCE, MCE and DD are late events in the course of MM, mainly observed in patients whose previous treatments included with novel drugs. They reflect a very aggressive disease behavior with shortened survival thereafter, probably due to the emergence of a new resistant clone. CD was mainly observed in patients secreting low IgG levels and FLCs, and possibly reflect IgG clone remission in biclonal patients, given that thereafter, the disease behaves as a usual multiple myeloma, secreting however the other clone. Disclosures: No relevant conflicts of interest to declare." @default.
• W98494543 created "2016-06-24" @default.
• W98494543 creator A5000383086 @default.
• W98494543 creator A5007546071 @default.
• W98494543 creator A5014713745 @default.
• W98494543 creator A5017828285 @default.
• W98494543 creator A5032438998 @default.
• W98494543 creator A5033750115 @default.
• W98494543 creator A5034761687 @default.
• W98494543 creator A5036299617 @default.
• W98494543 creator A5042276325 @default.
• W98494543 creator A5044092815 @default.
• W98494543 creator A5047138177 @default.
• W98494543 creator A5052052375 @default.
• W98494543 creator A5064642096 @default.
• W98494543 creator A5068927620 @default.
• W98494543 creator A5076305390 @default.
• W98494543 creator A5078995254 @default.
• W98494543 creator A5084509734 @default.
• W98494543 creator A5089931273 @default.
• W98494543 creator A5091524626 @default.
• W98494543 date "2013-11-15" @default.
• W98494543 modified "2023-09-28" @default.
• W98494543 title "Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients’ Course" @default.
• W98494543 doi "https://doi.org/10.1182/blood.v122.21.3173.3173" @default.
• W98494543 hasPublicationYear "2013" @default.
• W98494543 type Work @default.
• W98494543 sameAs 98494543 @default.
• W98494543 citedByCount "0" @default.
• W98494543 crossrefType "journal-article" @default.
• W98494543 hasAuthorship W98494543A5000383086 @default.
• W98494543 hasAuthorship W98494543A5007546071 @default.
• W98494543 hasAuthorship W98494543A5014713745 @default.
• W98494543 hasAuthorship W98494543A5017828285 @default.
• W98494543 hasAuthorship W98494543A5032438998 @default.
• W98494543 hasAuthorship W98494543A5033750115 @default.
• W98494543 hasAuthorship W98494543A5034761687 @default.
• W98494543 hasAuthorship W98494543A5036299617 @default.
• W98494543 hasAuthorship W98494543A5042276325 @default.
• W98494543 hasAuthorship W98494543A5044092815 @default.
• W98494543 hasAuthorship W98494543A5047138177 @default.
• W98494543 hasAuthorship W98494543A5052052375 @default.
• W98494543 hasAuthorship W98494543A5064642096 @default.
• W98494543 hasAuthorship W98494543A5068927620 @default.
• W98494543 hasAuthorship W98494543A5076305390 @default.
• W98494543 hasAuthorship W98494543A5078995254 @default.
• W98494543 hasAuthorship W98494543A5084509734 @default.
• W98494543 hasAuthorship W98494543A5089931273 @default.
• W98494543 hasAuthorship W98494543A5091524626 @default.
• W98494543 hasConcept C10515644 @default.
• W98494543 hasConcept C126322002 @default.
• W98494543 hasConcept C159654299 @default.
• W98494543 hasConcept C203014093 @default.
• W98494543 hasConcept C2776364478 @default.
• W98494543 hasConcept C2776553844 @default.
• W98494543 hasConcept C2778453870 @default.
• W98494543 hasConcept C2780898057 @default.
• W98494543 hasConcept C36394416 @default.
• W98494543 hasConcept C48010095 @default.
• W98494543 hasConcept C50382708 @default.
• W98494543 hasConcept C71924100 @default.
• W98494543 hasConcept C90924648 @default.
• W98494543 hasConceptScore W98494543C10515644 @default.
• W98494543 hasConceptScore W98494543C126322002 @default.
• W98494543 hasConceptScore W98494543C159654299 @default.
• W98494543 hasConceptScore W98494543C203014093 @default.
• W98494543 hasConceptScore W98494543C2776364478 @default.
• W98494543 hasConceptScore W98494543C2776553844 @default.
• W98494543 hasConceptScore W98494543C2778453870 @default.
• W98494543 hasConceptScore W98494543C2780898057 @default.
• W98494543 hasConceptScore W98494543C36394416 @default.
• W98494543 hasConceptScore W98494543C48010095 @default.
• W98494543 hasConceptScore W98494543C50382708 @default.
• W98494543 hasConceptScore W98494543C71924100 @default.
• W98494543 hasConceptScore W98494543C90924648 @default.
• W98494543 hasLocation W984945431 @default.
• W98494543 hasOpenAccess W98494543 @default.
• W98494543 hasPrimaryLocation W984945431 @default.
• W98494543 hasRelatedWork W128617204 @default.
• W98494543 hasRelatedWork W2005917948 @default.
• W98494543 hasRelatedWork W2070929611 @default.
• W98494543 hasRelatedWork W2122114383 @default.
• W98494543 hasRelatedWork W2262019827 @default.
• W98494543 hasRelatedWork W2522603840 @default.
• W98494543 hasRelatedWork W2526593839 @default.
• W98494543 hasRelatedWork W2551736000 @default.
• W98494543 hasRelatedWork W2559482013 @default.
• W98494543 hasRelatedWork W2564032099 @default.
• W98494543 hasRelatedWork W2566890130 @default.
• W98494543 hasRelatedWork W2570148831 @default.
• W98494543 hasRelatedWork W2572717150 @default.
• W98494543 hasRelatedWork W2573219103 @default.
• W98494543 hasRelatedWork W2578678001 @default.
• W98494543 hasRelatedWork W2594977443 @default.
• W98494543 hasRelatedWork W2599801691 @default.
• W98494543 hasRelatedWork W2611251398 @default.
• W98494543 hasRelatedWork W2911817676 @default.
• W98494543 hasRelatedWork W3187079037 @default.
• W98494543 isParatext "false" @default.
• W98494543 isRetracted "false" @default.

• next